PUBLISHER: Acute Market Reports | PRODUCT CODE: 1149154
PUBLISHER: Acute Market Reports | PRODUCT CODE: 1149154
Recombinant Plasma Protein Therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
Industry Outlook
The recombinant plasma protein therapeutics market is set to grow from US$ 8,435.3 Mn in 2021 to US$ 17,231.07 Mn in 2030 expanding at an annual growth rate of 8.3% during the forecast period from 2022 to 2030. According to World Federation of Hemophilia (WFH), approximately 1 in 1,000 people worldwide suffer with some form of bleeding disorder, 75% of them gain inadequate treatment and remain undiagnosed.
Lack of blood borne transmission disease and less severe effects in comparison to desmopressin popularizes recombinant coagulation factor VIII in treating hemophilia A
Recombinant coagulation factor VIII is leading the drug class segment for recombinant plasma protein therapeutics market. It is preferred over human plasma derive products to avoid potential transmission of blood borne infections. It is replacing desmopressin in treating mild hemophilia due to less adverse effects. Recombinant factor IX will gain growth momentum in the near future owing to recent FDA approval of Rebinyn (Novo Nordisk) for long term treatment of hemophilia B.
Ability to adapt growth conditions in serum free suspension, powerful gene amplification system and capacity for post translational modification drive the Chinese hamster ovary cell lines in recombinant protein synthesis
Since last 2 decades Chinese hamster ovarian cell lines have gained immense popularity over other cell lines such as baby hamster kidney cell lines and human embryonic kidney cell lines. Its ability to adapt growth conditions in serum free suspension, powerful gene amplifications and capacity for post translational modification proves its popularity as the most demanding cell line over others in recombinant protein syntheis.
High prevalence rate and 70 % of the diagnosed patients reported to suffer with severe form drive Hemophilia A market growth
Hemophilia A also known as clotting factor VIII deficiency or classical hemophilia is currently leading the indication segment for recombinant plasma protein therapeutics market. It has a high prevalence rate of 1 in 5000 people with approximately 70% diagnosed patients reported to be suffering with severe form of hemophilia A. The other type is Hemophilia B which is less common form with an occurrence rate of 1 in 25,000 people, it is caused due to lack of clotting factor IX. Von Willebrand disease is keen to register impressive growth in the near future due to high occurrence in blood group O type and rising public health awareness.
Rising prevalence of Hemophilia A and presence of a comprehensive network of federally funded treatment centers for hemophilia drive market growth in North America
North America is reigning the regional segment for recombinant plasma protein therapeutics market with a share of 40%. The chief factors controlling its market growth are rising prevalence of hemophilia A, according to the research findings of Center for Disease Control and Prevention (CDC), approximately 20,000 people are suffering with hemophilia in the United States. The existence of a comprehensive network of federally funded treatment centers for hemophilia cater to the medical aid of 70% patients with blood clotting disorders in North America region. Europe accounts for 30% market share due to increasing new born babies suffering with hemophilia. According to European Medical Agency (EMA) research findings annually 400 babies are born with hemophilia. Domicile of major players such as Novo Nordisk A/S, Bayer AG, Shire, Plc etc. bolster the market growth in Europe. Asia Pacific holds 20% market growth and is keen to register rapid growth during the forecast period owing to adoption of recombinant technology for protein synthesis and large patient pool suffering with blood clotting disorders.
Biotechnology companies manufacturing recombinant plasma proteins are: Aptevo Therapeutics, Bayer AG, Bioverativ Therapeutics, Inc., CSL Behring, Novo Nordisk A/S, Octapharma, Plc., Pfizer, Inc., Pharming Group NV, Shire, Plc. and Viropharma Biologics, Inc.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Recombinant Plasma Protein Therapeutics market are as follows:
- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
Geographical revenues generate by countries considered in the report:
Micro and macro environment factors that are currently influencing the Recombinant Plasma Protein Therapeutics market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
ATTRIBUTE DETAILS
- Research Period: 2020-2030
- Base Year: 2021
- Forecast Period: 2022-2030
- Historical Year: 2020
- Unit: USD Million
Market Segmentation
Drug Class
- Recombinant Factor VIII
- Recombinant Factor IX
Cell Line
- Chinese Hamster Ovary
- Baby Hamster Kidney
- Human Embryonic Kidney
- Others
Indication
- Hemophilia A
- Hemophilia B
- Von Willebrand Disease
- Others
Region Segment (2020-2030; US$ Million)
- North America
- U.S.
- Canada
- Rest of North America
- UK and European Union
- UK
- Germany
- Spain
- Italy
- France
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC
- Africa
- Rest of Middle East and Africa
Global Impact of COVID-19 Segment (2020-2021; US$ Million )
- Pre COVID-19 situation
- Post COVID-19 situation
Key questions answered in this report:
- What are the key micro and macro environmental factors that are impacting the growth of Recombinant Plasma Protein Therapeutics market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Recombinant Plasma Protein Therapeutics market?
- Which is the largest regional market for Recombinant Plasma Protein Therapeutics market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Recombinant Plasma Protein Therapeutics market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Recombinant Plasma Protein Therapeutics market worldwide?
Table of Contents
1. Preface
- 1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted
2. Executive Summary
- 2.1. Market Snapshot: Global Recombinant Plasma Protein Therapeutics Market
- 2.2. Global Recombinant Plasma Protein Therapeutics Market, By Drug Class, 2021 (US$ Million)
- 2.3. Global Recombinant Plasma Protein Therapeutics Market, By Cell Line, 2021 (US$ Million)
- 2.4. Global Recombinant Plasma Protein Therapeutics Market, By Indication, 2021 (US$ Million)
- 2.5. Global Recombinant Plasma Protein Therapeutics Market, By Geography, 2021 (US$ Million)
- 2.6. Impact of Covid 19
- 2.7. Attractive Investment Proposition by Geography, 2021
- 2.8. Competitive Analysis
- 2.8.1. Market Positioning of Key Recombinant Plasma Protein Therapeutics Market Vendors
- 2.8.2. Strategies Adopted by Recombinant Plasma Protein Therapeutics Market Vendors
- 2.8.3. Key Industry Strategies
3. Recombinant Plasma Protein Therapeutics Market: Business Outlook & Market Dynamics
- 3.1. Introduction
- 3.2. Global Recombinant Plasma Protein Therapeutics Market Value, 2020 - 2030, (US$ Million)
- 3.3. Market Dynamics
- 3.3.1. Market Drivers
- 3.3.2. Market Restraints
- 3.3.3. Key Challenges
- 3.3.4. Key Opportunities
- 3.4. Impact Analysis of Drivers and Restraints
- 3.5. See-Saw Analysis
- 3.6. Porter's Five Force Model
- 3.6.1. Supplier Power
- 3.6.2. Buyer Power
- 3.6.3. Threat Of Substitutes
- 3.6.4. Threat Of New Entrants
- 3.6.5. Competitive Rivalry
- 3.7. PESTEL Analysis
- 3.7.1. Political Landscape
- 3.7.2. Economic Landscape
- 3.7.3. Technology Landscape
- 3.7.4. Legal Landscape
- 3.7.5. Social Landscape
4. Recombinant Plasma Protein Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
- 4.1. Market Overview
- 4.2. Growth & Revenue Analysis: 2021 Versus 2030
- 4.3. Market Segmentation
- 4.3.1. Recombinant Factor VIII
- 4.3.2. Recombinant Factor IX
5. Recombinant Plasma Protein Therapeutics Market: By Cell Line, 2020-2030, USD (Million)
- 5.1. Market Overview
- 5.2. Growth & Revenue Analysis: 2021 Versus 2030
- 5.3. Market Segmentation
- 5.3.1. Chinese Hamster Ovary
- 5.3.2. Baby Hamster Kidney
- 5.3.3. Human Embryonic Kidney
- 5.3.4. Others
6. Recombinant Plasma Protein Therapeutics Market: By Indication, 2020-2030, USD (Million)
- 6.1. Market Overview
- 6.2. Growth & Revenue Analysis: 2021 Versus 2030
- 6.3. Market Segmentation
- 6.3.1. Hemophilia A
- 6.3.2. Hemophilia B
- 6.3.3. Von Willebrand Disease
- 6.3.4. Others
7. North America Recombinant Plasma Protein Therapeutics Market, 2020-2030, USD (Million)
- 7.1. Market Overview
- 7.2. Recombinant Plasma Protein Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
- 7.3. Recombinant Plasma Protein Therapeutics Market: By Cell Line, 2020-2030, USD (Million)
- 7.4. Recombinant Plasma Protein Therapeutics Market: By Indication, 2020-2030, USD (Million)
- 7.5.Recombinant Plasma Protein Therapeutics Market: By Region, 2020-2030, USD (Million)
- 7.5.1.North America
- 7.5.1.1. U.S.
- 7.5.1.2. Canada
- 7.5.1.3. Rest of North America
- 7.5.1.North America
8. UK and European Union Recombinant Plasma Protein Therapeutics Market, 2020-2030, USD (Million)
- 8.1. Market Overview
- 8.2. Recombinant Plasma Protein Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
- 8.3. Recombinant Plasma Protein Therapeutics Market: By Cell Line, 2020-2030, USD (Million)
- 8.4. Recombinant Plasma Protein Therapeutics Market: By Indication, 2020-2030, USD (Million)
- 8.5.Recombinant Plasma Protein Therapeutics Market: By Region, 2020-2030, USD (Million)
- 8.5.1.UK and European Union
- 8.5.1.1. UK
- 8.5.1.2. Germany
- 8.5.1.3. Spain
- 8.5.1.4. Italy
- 8.5.1.5. France
- 8.5.1.6. Rest of Europe
- 8.5.1.UK and European Union
9. Asia Pacific Recombinant Plasma Protein Therapeutics Market, 2020-2030, USD (Million)
- 9.1. Market Overview
- 9.2. Recombinant Plasma Protein Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
- 9.3. Recombinant Plasma Protein Therapeutics Market: By Cell Line, 2020-2030, USD (Million)
- 9.4. Recombinant Plasma Protein Therapeutics Market: By Indication, 2020-2030, USD (Million)
- 9.5.Recombinant Plasma Protein Therapeutics Market: By Region, 2020-2030, USD (Million)
- 9.5.1.Asia Pacific
- 9.5.1.1. China
- 9.5.1.2. Japan
- 9.5.1.3. India
- 9.5.1.4. Australia
- 9.5.1.5. South Korea
- 9.5.1.6. Rest of Asia Pacific
- 9.5.1.Asia Pacific
10. Latin America Recombinant Plasma Protein Therapeutics Market, 2020-2030, USD (Million)
- 10.1. Market Overview
- 10.2. Recombinant Plasma Protein Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
- 10.3. Recombinant Plasma Protein Therapeutics Market: By Cell Line, 2020-2030, USD (Million)
- 10.4. Recombinant Plasma Protein Therapeutics Market: By Indication, 2020-2030, USD (Million)
- 10.5.Recombinant Plasma Protein Therapeutics Market: By Region, 2020-2030, USD (Million)
- 10.5.1.Latin America
- 10.5.1.1. Brazil
- 10.5.1.2. Mexico
- 10.5.1.3. Rest of Latin America
- 10.5.1.Latin America
11. Middle East and Africa Recombinant Plasma Protein Therapeutics Market, 2020-2030, USD (Million)
- 11.1. Market Overview
- 11.2. Recombinant Plasma Protein Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
- 11.3. Recombinant Plasma Protein Therapeutics Market: By Cell Line, 2020-2030, USD (Million)
- 11.4. Recombinant Plasma Protein Therapeutics Market: By Indication, 2020-2030, USD (Million)
- 11.5.Recombinant Plasma Protein Therapeutics Market: By Region, 2020-2030, USD (Million)
- 11.5.1.Middle East and Africa
- 11.5.1.1. GCC
- 11.5.1.2. Africa
- 11.5.1.3. Rest of Middle East and Africa
- 11.5.1.Middle East and Africa
12. Company Profile
- 12.1. Aptevo Therapeutics.
- 12.1.1. Company Overview
- 12.1.2. Financial Performance
- 12.1.3. Product Portfolio
- 12.1.4. Strategic Initiatives
- 12.2. Bayer AG
- 12.2.1. Company Overview
- 12.2.2. Financial Performance
- 12.2.3. Product Portfolio
- 12.2.4. Strategic Initiatives
- 12.3. Bioverativ Therapeutics, Inc.
- 12.3.1. Company Overview
- 12.3.2. Financial Performance
- 12.3.3. Product Portfolio
- 12.3.4. Strategic Initiatives
- 12.4. CSL Behring
- 12.4.1. Company Overview
- 12.4.2. Financial Performance
- 12.4.3. Product Portfolio
- 12.4.4. Strategic Initiatives
- 12.5. Novo Nordisk A/S
- 12.5.1. Company Overview
- 12.5.2. Financial Performance
- 12.5.3. Product Portfolio
- 12.5.4. Strategic Initiatives
- 12.6. Octapharma, Plc.
- 12.6.1. Company Overview
- 12.6.2. Financial Performance
- 12.6.3. Product Portfolio
- 12.6.4. Strategic Initiatives
- 12.7. Pfizer, Inc.
- 12.7.1. Company Overview
- 12.7.2. Financial Performance
- 12.7.3. Product Portfolio
- 12.7.4. Strategic Initiatives
- 12.8. Pharming Group NV
- 12.8.1. Company Overview
- 12.8.2. Financial Performance
- 12.8.3. Product Portfolio
- 12.8.4. Strategic Initiatives
- 12.9. Shire, Plc.
- 12.9.1. Company Overview
- 12.9.2. Financial Performance
- 12.9.3. Product Portfolio
- 12.9.4. Strategic Initiatives
- 12.10. Viropharma Biologics, Inc.
- 12.10.1. Company Overview
- 12.10.2. Financial Performance
- 12.10.3. Product Portfolio
- 12.10.4. Strategic Initiatives
List of Tables
- TABLE 1 Global Recombinant Plasma Protein Therapeutics Market By Drug Class, 2020-2030, USD (Million)
- TABLE 2 Global Recombinant Plasma Protein Therapeutics Market By Cell Line, 2020-2030, USD (Million)
- TABLE 3 Global Recombinant Plasma Protein Therapeutics Market By Indication, 2020-2030, USD (Million)
- TABLE 4 North America Recombinant Plasma Protein Therapeutics Market By Drug Class, 2020-2030, USD (Million)
- TABLE 5 North America Recombinant Plasma Protein Therapeutics Market By Cell Line, 2020-2030, USD (Million)
- TABLE 6 North America Recombinant Plasma Protein Therapeutics Market By Indication, 2020-2030, USD (Million)
- TABLE 7 UK and European Union Recombinant Plasma Protein Therapeutics Market By Drug Class, 2020-2030, USD (Million)
- TABLE 8 UK and European Union Recombinant Plasma Protein Therapeutics Market By Cell Line, 2020-2030, USD (Million)
- TABLE 9 UK and European Union Recombinant Plasma Protein Therapeutics Market By Indication, 2020-2030, USD (Million)
- TABLE 10 Asia Pacific Recombinant Plasma Protein Therapeutics Market By Drug Class, 2020-2030, USD (Million)
- TABLE 11 Asia Pacific Recombinant Plasma Protein Therapeutics Market By Cell Line, 2020-2030, USD (Million)
- TABLE 12 Asia Pacific Recombinant Plasma Protein Therapeutics Market By Indication, 2020-2030, USD (Million)
- TABLE 13 Latin America Recombinant Plasma Protein Therapeutics Market By Drug Class, 2020-2030, USD (Million)
- TABLE 14 Latin America Recombinant Plasma Protein Therapeutics Market By Cell Line, 2020-2030, USD (Million)
- TABLE 15 Latin America Recombinant Plasma Protein Therapeutics Market By Indication, 2020-2030, USD (Million)
- TABLE 16 Middle East and Africa Recombinant Plasma Protein Therapeutics Market By Drug Class, 2020-2030, USD (Million)
- TABLE 17 Middle East and Africa Recombinant Plasma Protein Therapeutics Market By Cell Line, 2020-2030, USD (Million)
- TABLE 18 Middle East and Africa Recombinant Plasma Protein Therapeutics Market By Indication, 2020-2030, USD (Million)
List of Figures
- FIG. 1 Global Recombinant Plasma Protein Therapeutics Market: Market Coverage
- FIG. 2 Research Methodology and Data Sources
- FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
- FIG. 4 Global Recombinant Plasma Protein Therapeutics Market: Quality Assurance
- FIG. 5 Global Recombinant Plasma Protein Therapeutics Market, By Drug Class, 2021
- FIG. 6 Global Recombinant Plasma Protein Therapeutics Market, By Cell Line, 2021
- FIG. 7 Global Recombinant Plasma Protein Therapeutics Market, By Indication, 2021
- FIG. 8 Global Recombinant Plasma Protein Therapeutics Market, By Geography, 2021
- FIG. 9 Global Recombinant Plasma Protein Therapeutics Market, By Drug Class, 2021 Vs 2030, %
- FIG. 10 Global Recombinant Plasma Protein Therapeutics Market, By Cell Line, 2021 Vs 2030, %
- FIG. 11 Global Recombinant Plasma Protein Therapeutics Market, By Indication, 2021 Vs 2030, %
- FIG. 12 U.S. Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
- FIG. 13 Canada Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
- FIG. 14 Rest of North America Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
- FIG. 15 UK Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
- FIG. 16 Germany Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
- FIG. 17 Spain Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
- FIG. 18 Italy Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
- FIG. 19 France Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
- FIG. 20 Rest of Europe Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
- FIG. 21 China Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
- FIG. 22 Japan Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
- FIG. 23 India Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
- FIG. 24 Australia Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
- FIG. 25 South Korea Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
- FIG. 26 Rest of Asia Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
- FIG. 27 Brazil Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
- FIG. 28 Mexico Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
- FIG. 29 Rest of Latin America Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
- FIG. 30 GCC Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
- FIG. 31 Africa Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
- FIG. 32 Rest of Middle East and Africa Recombinant Plasma Protein Therapeutics Market (US$ Million), 2020 - 2030
